Nacimbio will invest 2.2 billion rubles in vaccine manufacturing

| By | FORT, Import Substitution, Nacimbio, Vaccine Production

The Governor of the Ryazan region Nikolay Lyubimov and Anton Katlinsky, the President of FORT LLC, a part of Nacimbio pharmaceutical holding company of Rostec Corporation, have signed an agreement to extend the provision of state support to the enterprise until 2022.

The previous investment agreement was concluded in 2011 to support the investment project on creation of innovative complex for the development, implementation and manufacturing of medicines based on biotechnology and nanotechnology. This support was provided in the form of 4% reduction of the income tax paid to the regional budget and 1.6% reduction of the property tax rate. The total amount of state support in the form of benefits on taxes paid to the regional budget will be 625 million rubles, and the amount of tax deductions by Fort LLC will exceed 1.5 billion rubles.

The decision to extend the agreement was taken by the government of the Ryazan region and is caused by significant changes of the of investment project parameters.

After the signing of previous agreement, the investments in the plant increased by 2.2 billion rubles and will reach 5.7 billion rubles.  These funds will be used to expand the range of immunobiological products and, in particular, to launch the manufacturing of vaccines against varicella, measles, rubella, and rotavirus. This will allow the company to become the only local full-cycle manufacturer of this drugs type.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.